Aldevron Breakthrough Blog
Providing Leadership
September 22, 2025 by Aldevron
Genetic Engineering & Biotechnology News highlights Aldevron
We’re excited to be featured in Genetic Engineering & Biotechnology News this month as a CDMO leading the way.
Our recent role in the successful treatment of “Baby KJ” with the world’s first mRNA-based personalized CRISPR therapy highlights the critical role CDMOs play in advancing biomanufacturing.
From manufacturing the RNA for groundbreaking therapies like this, to enabling integrated, end-to-end mRNA drug product manufacturing under one roof, Aldevron is raising the bar for speed, scalability, and quality in bioprocessing.
As Aldevron president, Jennifer Meade said, “We are helping to set a new standard in the bioprocessing industry, particularly for personalized and scalable mRNA-based therapies.”
Read the article from Genetic Engineering & Biotechnology News
- Learn more about the Baby KJ Story
- Visit our RNA Synthesis and Manufacturing page
- Visit our Gene Editing Modality page
- Have questions on this topic? Contact Us
- Have an idea for a topic? Let us know!
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. You can follow the company on LinkedIn, Facebook and YouTube.